A Boston VC firm is launching a new neuroscience company with a $93M investment that aims to treat disorders including ...

Auron Therapeutics has raised a $27 million Series B financing that it will use to initiate clinical development of its lead experimental drug, AUTX-703, in blood cancers.

Allogene Therapeutics (ALLO) announced the publication of data from its Phase 1 ALPHA and ALPHA2 clinical studies of cemacabtagene ...

Aclaris Therapeutics (ACRS) announced the availability of a new publication describing properties of Aclaris Therapeutics’ ATI-2138, a novel ...

Lineage Cell Therapeutics initiates DOSED clinical study of OPC1 for spinal cord injury: Carlsbad, California Thursday, February 13, 2025, 14:00 Hrs [IST] Lineage Cell Therapeutic ...

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic ...

The results from Phase 1 of the Troculeucel Clinical Trial demonstrated stable/improved outcomes in 90% of subjects, with no drug-related adverse events following troculeucel therapy. Troculeucel ...

Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25. If approved, FILSPARI could be the first and only approv ...

--(BUSINESS WIRE)--Blackstone Life Sciences and Anthos Therapeutics ... 71 were recently published in the New England Journal of Medicine on January 23, 2025. Anthos is currently conducting a phase 3 ...

The pharmaceutical giant said it has agreed to acquire the U.S. privately held, clinical-stage biopharmaceutical company to ...

According to the scientists, study participants had fewer days to recover from the illnesses when compared to the standard of ...